Company: LRHC
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-079984
Chunk: 29

Company: La Rosa Holdings Corp.
Filing Date: 2025-08-22
Form: 424B3
Chunk 29
---
holder,
or anticipation of such sales, could cause the trading price of our common stock to decline or make it more difficult for us to sell equity
or equity-related securities in the future at a time and at a price that we might otherwise desire.

We may not have access to the full amount available under the Facility with the Selling Stockholder. We may require additional financing to sustain our operations, without which we may not be able to continue operations, and the terms of subsequent financings may adversely impact our stockholders.

We may direct the Selling Stockholder to purchase up to $150,000,000
worth of shares of our common stock in a “regular purchase” (as set forth in the Facility) from time to time under the Facility
over a 36-month period generally in amounts of shares of common stock that vary depending on the closing sale price of our common stock
at the time of sale. Moreover, under certain circumstances as set forth in the Facility, we may, in our sole discretion, also direct the Selling Stockholder
to purchase additional shares of common stock in “accelerated purchases” as set forth in the Facility.

<div align='center'>15</div>

Depending on the prevailing market price of
our common stock, we may not be able to sell shares to the Selling Stockholder for the maximum $150,000,000 over the term of the
Facility. In addition, the Selling Stockholder will not be required to purchase any shares of our common stock if such sale would result in
the Selling Stockholder’s stock exceeding the 4.99% (which the Selling Stockholder, upon notice to the Company, may increase or
decrease but in no event in excess of 9.99%) of the outstanding voting power or number of the common stock. Our inability to access
a portion or the full amount available under the Facility, in the absence of any other financing sources, could have a material
adverse effect on our business.

If obtaining sufficient funding from the Selling Stockholder were
to prove unavailable or prohibitively dilutive, we will need to secure another source of capital in order to satisfy our working capital
needs.

Our management will have broad discretion over the use of the net proceeds, if any, from sales of shares of our common stock to the Selling Stockholder, and you may not agree with how we use the proceeds and the proceeds may not be used effectively.

This Prospectus relates to shares of our common
stock that may be offered and sold from time